Developed skills and lines of research
Paola Signorelli graduated with honors in Biology in 1994 and obtained a PhD in Experimental Medicine in 1999 from La Sapienza University of Rome. She is currently an associate professor of Biochemistry at the University of Milan. In the Sphingolipid Biochemistry Laboratory (Department of Health Sciences, University of Milan), of which she is co-responsible, a research fellow, three PhD students, and two technicians work. In the field of cystic fibrosis, Paola Signorelli is working on new drugs with possible anti-inflammatory and antifungal action: sphingolipid inhibitors; experimentation on animal models is planned.
Projects funded by FFC Ricerca as Principal Investigator or as Research Manager
FFC#11/2016
Myriocin potential as a phenotype-modifyingt therapeutical in cystic fibrosis
FFC#20/2013
Sphingolipid targeting in inflammation and fungal infection
Publications from FFC Research projects
Ghidoni R, Caretti A, Signorelli P. Role of Sphingolipids in the pathobiology of lung inflammation. Mediators Inflamm, 2015;2015:487508. doi: 10.1155/2015/487508. Epub 2015 Dec 3.
Caretti A, Torelli R, Perdoni F, et al. Inhibition of ceramide de novo synthesis by myriocin produces the double effect of reducing pathological inflammation and exerting antifungal activity against A. fumigatus airways infection. Biochim Biophys Acta. 2016 Jun;1860(6):1089-97. doi: 10.1016/j.bbagen.2016.02.014. Epub 2016 Feb 24.
Caretti A, Vasso M, Bonezzi FT et al. Myriocin treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids. Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug;390(8):775-790. doi: 10.1007/s00210-017-1373-4. Epub 2017 Apr 24.
Alessandra Mingione, Emeranziana Ottaviano, Fabiola Bonezzi, Michele dei Cas, Marco Piccoli, Matteo Barcella, Anna Caretti, Rita Paroni, Riccardo Ghidoni, Natalia Cirilli, Elisa Borghi, Paola Signorelli. Myriocin potential as a phenotype-modifying therapeutical in Cystic Fibrosis. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14 (Suppl 1):5